Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Leqvio
Pharma
Novartis CEO shrugs off oral PCSK9 threat amid Q2 growth
Novartis' CEO remains unfazed by the threat of Merck's newly approved oral PCSK9 inhibitor, Lipfendra, to his company's injectable Leqvio.
Angus Liu
Jul 21, 2026 10:36am
FDA approves an oral PCSK9 med for 1st time in Merck's Lipfendra
Jul 16, 2026 9:30am
Newer drugs came to Novartis' aid as top-selling brands stalled
Oct 28, 2025 11:18am
Novartis to lay off 427 staffers amid marketing model rework
Mar 18, 2025 10:19am
Novartis pads case for broader use of heart med Leqvio
Aug 28, 2024 11:29am
Novartis scraps key UK Leqvio study
Mar 22, 2023 11:55am
